Distinguished in Plaque Psoriasis

Dr. William Abramovits

Dermatology
Bare Derm. Group Inc.
2110 Research Row Ste 310, 
Dallas, TX 
Offers Telehealth
Distinguished in Plaque Psoriasis
Bare Derm. Group Inc.
2110 Research Row Ste 310, 
Dallas, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

William Abramovits is a Dermatologist in Dallas, Texas. Dr. Abramovits is rated as a Distinguished provider by MediFind in the treatment of Plaque Psoriasis. His top areas of expertise are Plaque Psoriasis, Psoriasis, Atopic Dermatitis, and Seborrheic Keratosis.

His clinical research consists of co-authoring 80 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 13 articles and participated in 4 clinical trials in the study of Plaque Psoriasis.

Specialties
Dermatology
Licenses
Dermatology in TX
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Baylor Scott & White Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community Health Choice
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Home State Health
  • EPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
TeamCare
  • OTHER COMMERCIAL
The Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
  • OTHER MEDICARE PART D
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 21 Less Insurance Carriers -

Locations

Bare Derm. Group Inc.
2110 Research Row Ste 310, Dallas, TX 75235
Call: 972-213-6210

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Enrollment Status: Completed
Publish Date: November 05, 2025
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
Safety and Effect of LEO 90100 Aerosol Foam on the HPA Axis and Calcium Metabolism in Adolescent Subjects (Aged 12 to < 17 Years) With Plaque Psoriasis
Safety and Effect of LEO 90100 Aerosol Foam on the HPA Axis and Calcium Metabolism in Adolescent Subjects (Aged 12 to < 17 Years) With Plaque Psoriasis
Enrollment Status: Completed
Publish Date: March 10, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Pragmatic Trial of Home Versus Office Based Narrow Band Ultraviolet B Phototherapy for the Treatment of Psoriasis
A Pragmatic Trial of Home Versus Office Based Narrow Band Ultraviolet B Phototherapy for the Treatment of Psoriasis
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Device
Study Phase: Not Applicable
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Trial to Evaluate the Efficacy and Safety of ASLAN004 in Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Trial to Evaluate the Efficacy and Safety of ASLAN004 in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: April 26, 2024
Intervention Type: Drug, Biological
Study Drug: ASLAN004
Study Phase: Phase 2
A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Phase 2 Dose-Response Study to Determine Safety and Effectiveness of Two Concentrations of NFX-179 Gel in Subjects With Cutaneous Neurofibromas
A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Phase 2 Dose-Response Study to Determine Safety and Effectiveness of Two Concentrations of NFX-179 Gel in Subjects With Cutaneous Neurofibromas
Enrollment Status: Completed
Publish Date: November 18, 2023
Intervention Type: Drug
Study Drug: NFX-179
Study Phase: Phase 2
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Drug
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Phase 2, Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
A Phase 2, Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
Enrollment Status: Terminated
Publish Date: September 18, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double-blind, Placebo-controlled, Phase 2B Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
A Randomized, Double-blind, Placebo-controlled, Phase 2B Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: July 03, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Phase II, Multicenter, Double-blind, Double-dummy, Placebo Controlled, Randomized Study to Evaluate the Efficacy and Safety of AUR101 in Patients With Moderate-to-Severe Psoriasis (INDUS-3)
A Phase II, Multicenter, Double-blind, Double-dummy, Placebo Controlled, Randomized Study to Evaluate the Efficacy and Safety of AUR101 in Patients With Moderate-to-Severe Psoriasis (INDUS-3)
Enrollment Status: Completed
Publish Date: December 13, 2022
Intervention Type: Drug
Study Drug: AUR101
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate The Efficacy and Safety of Lebrikizumab When Used In Combination With Topical Corticosteroid Treatment In Patients With Moderate-To-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate The Efficacy and Safety of Lebrikizumab When Used In Combination With Topical Corticosteroid Treatment In Patients With Moderate-To-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: May 09, 2022
Intervention Type: Other, Biological
Study Drugs: Lebrikizumab, Topical Corticosteroid
Study Phase: Phase 3
A Multiple-Dose, Randomized, Placebo-Controlled, Study of LY3462817 or LY3509754 in Patients With Psoriasis
A Multiple-Dose, Randomized, Placebo-Controlled, Study of LY3462817 or LY3509754 in Patients With Psoriasis
Enrollment Status: Terminated
Publish Date: March 15, 2022
Intervention Type: Drug
Study Drugs: LY3462817-IV, LY3462817-SV
Study Phase: Phase 1
A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis
A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis
Enrollment Status: Completed
Publish Date: July 28, 2020
Intervention Type: Drug
Study Phase: Phase 4
A Phase 2 Multicenter Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of Asimadoline in Adult Subjects With Pruritus Associated With Atopic Dermatitis
A Phase 2 Multicenter Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of Asimadoline in Adult Subjects With Pruritus Associated With Atopic Dermatitis
Enrollment Status: Completed
Publish Date: December 13, 2017
Intervention Type: Drug
Study Phase: Phase 2
View 12 Less Clinical Trials

80 Total Publications

ZelsuvmiTM (Berdazimer) Topical Gel.
ZelsuvmiTM (Berdazimer) Topical Gel.
Journal: Skinmed
Published: January 03, 2025
View All 80 Publications
Similar Doctors
Distinguished in Plaque Psoriasis
Dr. Jennifer C. Cather
Dermatology
Distinguished in Plaque Psoriasis
Dr. Jennifer C. Cather
Dermatology

Mindful Dermatology, PA

9101 N. Central Expressway, Suite 160, 
Dallas, TX 
 (6.0 miles away)
972-449-0540
Experience:
32+ years
Languages Spoken:
English
See accepted insurances

Jennifer Cather is a Dermatologist in Dallas, Texas. Dr. Cather has been practicing medicine for over 32 years and is rated as a Distinguished provider by MediFind in the treatment of Plaque Psoriasis. Her top areas of expertise are Psoriasis, Plaque Psoriasis, Neurocutaneous Melanosis, and Giant Congenital Nevus.

Distinguished in Plaque Psoriasis
Dr. Martin Menter
Dermatology
Distinguished in Plaque Psoriasis
Dr. Martin Menter
Dermatology

Magnolia Obstetrics & Gynecology PLLC

3900 Junius St Ste 145, 
Dallas, TX 
 (6.4 miles away)
972-386-7546
Languages Spoken:
English
See accepted insurances

Martin Menter is a Dermatologist in Dallas, Texas. Dr. Menter is rated as a Distinguished provider by MediFind in the treatment of Plaque Psoriasis. His top areas of expertise are Plaque Psoriasis, Psoriasis, Seborrheic Keratosis, and Warts.

Distinguished in Plaque Psoriasis
Dr. Bryan A. Selkin
Dermatology
Distinguished in Plaque Psoriasis
Dr. Bryan A. Selkin
Dermatology

Signature Dermatology & Aesthetics - Plano

5060 Tennyson Pkwy, Ste 100, 
Plano, TX 
 (16.7 miles away)
972-505-2551
Languages Spoken:
English, Spanish
See accepted insurances
Offers Telehealth

Bryan Selkin is a Dermatologist in Plano, Texas. Dr. Selkin is rated as a Distinguished provider by MediFind in the treatment of Plaque Psoriasis. His top areas of expertise are Giant Congenital Nevus, Familial Atypical Multiple Mole Melanoma Syndrome, Giant Congenital Melanocytic Nevus, and Neurocutaneous Melanosis.

VIEW MORE PLAQUE PSORIASIS DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Abramovits's expertise for a condition
ConditionClose
    • Distinguished
    • Atopic Dermatitis
      Dr. Abramovits is
      Distinguished
      . Learn about Atopic Dermatitis.
      See more Atopic Dermatitis experts
    • Plaque Psoriasis
      Dr. Abramovits is
      Distinguished
      . Learn about Plaque Psoriasis.
      See more Plaque Psoriasis experts
    • Psoriasis
      Dr. Abramovits is
      Distinguished
      . Learn about Psoriasis.
      See more Psoriasis experts
    • Advanced
    • Acne
      Dr. Abramovits is
      Advanced
      . Learn about Acne.
      See more Acne experts
    • Alopecia Areata
      Dr. Abramovits is
      Advanced
      . Learn about Alopecia Areata.
      See more Alopecia Areata experts
    • Folliculitis
      Dr. Abramovits is
      Advanced
      . Learn about Folliculitis.
      See more Folliculitis experts
    • Molluscum Contagiosum
      Dr. Abramovits is
      Advanced
      . Learn about Molluscum Contagiosum.
      See more Molluscum Contagiosum experts
    • Pustules
      Dr. Abramovits is
      Advanced
      . Learn about Pustules.
      See more Pustules experts
    • Ringworm
      Dr. Abramovits is
      Advanced
      . Learn about Ringworm.
      See more Ringworm experts
    View All 7 Advanced Conditions
    • Experienced
    • Actinic Keratosis
      Dr. Abramovits is
      Experienced
      . Learn about Actinic Keratosis.
      See more Actinic Keratosis experts
    • Athlete's Foot
      Dr. Abramovits is
      Experienced
      . Learn about Athlete's Foot.
      See more Athlete's Foot experts
    • Autoerythrocyte Sensitivity
      Dr. Abramovits is
      Experienced
      . Learn about Autoerythrocyte Sensitivity.
      See more Autoerythrocyte Sensitivity experts
    • Autosomal Recessive Hypotrichosis
      Dr. Abramovits is
      Experienced
      . Learn about Autosomal Recessive Hypotrichosis.
      See more Autosomal Recessive Hypotrichosis experts
    • Basal Cell Skin Cancer
      Dr. Abramovits is
      Experienced
      . Learn about Basal Cell Skin Cancer.
      See more Basal Cell Skin Cancer experts
    • Cerebral Cavernous Malformation
      Dr. Abramovits is
      Experienced
      . Learn about Cerebral Cavernous Malformation.
      See more Cerebral Cavernous Malformation experts
    View All 31 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2026 All Rights Reserved

      Request an Appointment

      If you are experiencing a medical emergency, call 9-1-1.

      MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

      Patient Details

      This information is for the patient who will be seen at the appointment.

        Close

        Returning patient? Use your address on file with the provider.

        Insurance Details

        Please provide information of the primary insurance holder as the practice may require this information to schedule.

        Insurance Provider *
        Insurance ProviderClose

        Appointments Details

        Let’s get more information about your appointment.

                0 / 1000
                0 / 1000
                By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.